IP Library Granted Patent US 9,012,433
Granted Patent B2
US 9,012,433 · App. 13/686,639 · Granted Apr 21, 2015

Substituted tetracycline compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,012,433
App. No.
13/686,639
Granted
Apr 21, 2015
Kind
B2
Abstract

The present invention pertains to tetracycline compounds of formula (VIIa): R 5* , R 5*′ , R 7r* , and R 9m* are defined herein. These tetracycline compounds can be used to treat tetracycline compound-responsive states, such as multiple sclerosis and rheumatoid arthritis.

Claims (21)

1. A tetracycline compound of formula (VIIa):

wherein

X is CR 6* CR 6* ;

R 5* is hydrogen;

R 5*′ is hydrogen hydroxyl;

R 6*′ is hydrogen or alkyl;

R 6* is hydrogen;

R 7r* alkylamino; and

R 9m* is oxazolyl or isoxazolyl, or a pharmaceutically acceptable salt thereof.

2. The tetracycline compound of claim 1 , wherein oxazolyl is substituted with methyl or isopropyl.

3. The tetracycline compound of claim 1 , wherein R 7r* is dialkylamino.

4. The tetracycline compound of claim 1 , wherein R 7r* is dimethylamino.

5. The tetracycline compound of claim 1 , wherein each of R 5* , R 5*′ , R 6* , and R 6*′ is hydrogen.

6. The tetracycline compound of claim 5 , wherein R 7r* is dialkylamino.

7. The tetracycline compound of claim 6 , wherein R 7r* is dimethylamino.

8. The tetracycline compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a tetracycline compound of claim 1 and a pharmaceutical acceptable carrier.

10. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

11. A method for treating multiple sclerosis in a subject, comprising administering to said subject an effective amount of a tetracycline compound of any one of claims 1 , 2 , 3 to 7 , 8 or 10 , such that said subject is treated.

Assignments (9)
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL/FRAME 71200/0656 Recorded Mar 17, 2026
From: OAKTREE FUND ADMINISTRATION, LLC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 075101/0815 →
PATENT SECURITY AGREEMENT Recorded Mar 16, 2026
From: PARATEK PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 075111/0244 →
SECURITY INTEREST Recorded May 22, 2025
From: PARATEK PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 071200/0656 →
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL/FRAME 065001/0917 Recorded May 22, 2025
From: OAKTREE FUND ADMINISTRATION, LLC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 071343/0407 →
SECURITY INTEREST Recorded Sep 22, 2023
From: PARATEK PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 065001/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2015
From: ABATO, PAUL; BOWSER, TODD
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 035259/0880 →
TERMINATION OF LIEN ON PATENTS Recorded Dec 23, 2014
From: MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034700/0377 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2014
From: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034113/0910 →
SECURITY INTEREST Recorded Mar 14, 2014
From: PARATEK PHARMACEUTICALS, INC.
To: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
Reel/Frame 032448/0001 →